MTR and meningioma: Evidence from a previous meta-analysis (30) demonstrated that the methylenetetrahydrofolate reductase C677T polymorphism may modify the risk of meningioma, whereas another meta-analysis (22) reported that the MTR rs1805087 polymorphism exhibited no significant association with meningioma.